Intech Investment Management LLC lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 29.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,870 shares of the company’s stock after selling 1,220 shares during the period. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $1,398,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in shares of IDEXX Laboratories by 15.5% during the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after acquiring an additional 1,839 shares during the last quarter. Manning & Napier Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $20,418,000. Brevan Howard Capital Management LP purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $3,183,000. First Hawaiian Bank acquired a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $982,000. Finally, Meyer Handelman Co. purchased a new position in shares of IDEXX Laboratories during the first quarter valued at approximately $2,155,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Down 0.3 %
IDXX opened at $506.38 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm has a 50 day moving average price of $484.48 and a 200 day moving average price of $497.97. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The company has a market cap of $41.82 billion, a PE ratio of 49.02, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33.
Analysts Set New Price Targets
Several brokerages have weighed in on IDXX. Piper Sandler cut their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.
Read Our Latest Report on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
- Five stocks we like better than IDEXX Laboratories
- Insider Trades May Not Tell You What You Think
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The Role Economic Reports Play in a Successful Investment Strategy
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What Are Some of the Best Large-Cap Stocks to Buy?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.